Regeneron Pharmaceuticals Inc

자세한 내용은 Regeneron Pharmaceuticals Inc 회사

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.

회사 정보

종목 코드 REGN

회사 이름Regeneron Pharmaceuticals Inc

상장일Apr 02, 1991

CEODr. Leonard S. Schleifer, M.D., Ph.D

직원 수15106

유형Ordinary Share

회계 연도 종료Apr 02

주소777 Old Saw Mill River Road

도시TARRYTOWN

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호10591

전화17813705000

웹사이트https://www.regeneron.com/

종목 코드 REGN

상장일Apr 02, 1991

CEODr. Leonard S. Schleifer, M.D., Ph.D

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.42K

+0.05%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

19.75K

+20.78%

Mr. Arthur F. (Art) Ryan

Independent Director

17.66K

-0.10%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.37K

+9.94%

Dr. Michael S. Brown, M.D.

Independent Director

12.62K

-0.13%

이름

이름/직위

직위

주식 보유

변동

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

53.42K

+0.05%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

Sanofi

1.18B

39.07%

EYLEA

736.00M

24.30%

Bayer

343.90M

11.35%

EYLEA HD

306.80M

10.13%

Libtayo

192.50M

6.36%

기타

266.30M

8.79%

데이터 없음

사업별

지역별

사업별USD

이름

수익

비율

Sanofi

1.18B

39.07%

EYLEA

736.00M

24.30%

Bayer

343.90M

11.35%

EYLEA HD

306.80M

10.13%

Libtayo

192.50M

6.36%

기타

266.30M

8.79%

주식 보유 통계

마지막 업데이트: Sat, Aug 30

주주

주주 유형

주주

비율

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

5.44%

State Street Global Advisors (US)

4.64%

Dodge & Cox

3.67%

Fidelity Management & Research Company LLC

3.13%

기타

74.12%

주주

비율

The Vanguard Group, Inc.

9.00%

BlackRock Institutional Trust Company, N.A.

5.44%

State Street Global Advisors (US)

4.64%

Dodge & Cox

3.67%

Fidelity Management & Research Company LLC

3.13%

기타

74.12%

주주 유형

주주

비율

Investment Advisor

47.67%

Investment Advisor/Hedge Fund

28.51%

Hedge Fund

5.34%

Research Firm

2.70%

Pension Fund

2.54%

Bank and Trust

2.15%

Individual Investor

2.01%

Sovereign Wealth Fund

1.22%

Insurance Company

0.08%

기타

7.78%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

2585

99.72M

95.69%

-2.03M

2025Q1

2621

99.84M

93.97%

-1.42M

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

2023Q2

2360

99.25M

92.00%

-1.42M

2023Q1

2366

99.66M

92.70%

-1.10M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

The Vanguard Group, Inc.

9.36M

8.81%

+117.55K

+1.27%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

5.74M

5.41%

+45.93K

+0.81%

Mar 31, 2025

State Street Global Advisors (US)

4.79M

4.51%

-42.58K

-0.88%

Mar 31, 2025

Dodge & Cox

2.32M

2.19%

+2.77K

+0.12%

Mar 31, 2025

Fidelity Management & Research Company LLC

7.40M

6.97%

-573.19K

-7.19%

Mar 31, 2025

Capital International Investors

3.99M

3.76%

-747.80K

-15.79%

Mar 31, 2025

JP Morgan Asset Management

4.08M

3.84%

-1.16M

-22.19%

Mar 31, 2025

Geode Capital Management, L.L.C.

2.47M

2.33%

+41.95K

+1.73%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

2.19M

2.07%

-36.81K

-1.65%

Jun 30, 2025

Putnam Investment Management, L.L.C.

1.91M

1.8%

+285.04K

+17.50%

Mar 31, 2025

575.060USD

Regeneron Pharmaceuticals Inc

575.060

개요

회사

금융

분석